AJP - GI Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol 297: G611-G618, 2009. First published July 16, 2009; doi:10.1152/ajpgi.90644.2008
0193-1857/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
297/3/G611    most recent
90644.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Wanninger, J.
Right arrow Articles by Buechler, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wanninger, J.
Right arrow Articles by Buechler, C.

HORMONES AND SIGNALING

Adiponectin-stimulated CXCL8 release in primary human hepatocytes is regulated by ERK1/ERK2, p38 MAPK, NF-{kappa}B, and STAT3 signaling pathways

Josef Wanninger,1 Markus Neumeier,1 Johanna Weigert,1 Sabrina Bauer,1 Thomas S. Weiss,2 Andreas Schäffler,1 Corinna Krempl,1 Cornelia Bleyl,1 Charalampos Aslanidis,3 Jürgen Schölmerich,1 and Christa Buechler1

Departments of 1Internal Medicine I and 2Surgery and Center for Liver Cell Research, 3Institute of Clinical Chemistry and Laboratory Medicine, University Hospital of Regensburg, Regensburg, Germany

Submitted 10 November 2008 ; accepted in final form 15 July 2009

Adiponectin is believed to exert hepatoprotective effects and induces CXCL8, a chemokine that functions as a survival factor, in vascular cells. In the current study, it is demonstrated that adiponectin also induces CXCL8 expression in primary human hepatocytes but not in hepatocellular carcinoma cell lines. Knock down of the adiponectin receptor (AdipoR) 1 or AdipoR2 by small-interfering RNA indicates that AdipoR1 is involved in adiponectin-stimulated CXCL8 release. Adiponectin activates nuclear factor (NF)-{kappa}B in primary hepatocytes and pharmacological inhibition of NF-{kappa}B, the p38 mitogen-activated protein kinase, and extracellular signal-regulated kinase (ERK) 1/ERK2 reduces adiponectin-mediated CXCL8 secretion. Furthermore, adiponectin also activates STAT3 involved in interleukin (IL)-6 and leptin-mediated CXCL8 induction in primary hepatocytes. Inhibition of JAK2 by AG-490 does not abolish adiponectin-stimulated CXCL8, indicating that this kinase is not involved. Pretreatment of primary cells with "STAT3 Inhibitor VI," however, elevates hepatocytic CXCL8 secretion, demonstrating that STAT3 is a negative regulator of CXCL8 in these cells. In accordance with this assumption, IL-6, a well-characterized activator of STAT3, reduces hepatocytic CXCL8. Therefore, adiponectin-stimulated induction of CXCL8 seems to be tightly controlled in primary human hepatocytes, whereas neither NF-{kappa}B, STAT3, nor CXCL8 are influenced in hepatocytic cell lines. CXCL8 is a survival factor, and its upregulation by adiponectin may contribute to the hepatoprotective effects of this adipokine.

adiponectin; hepatocyte; nuclear factor-{kappa}B; adiponectin receptor 1; STAT3; extracellular signal-regulated kinase; mitogen-activated protein kinase



Address for reprint requests and other correspondence: C. Buechler, Department of Internal Medicine I, University Hospital of Regensburg, Regensburg 93042, Germany (e-mail: christa.buechler{at}klinik.uni-regensburg.de)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.